Opko Health Inc (OPK:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry
Key Findings: - Unique new report provides deep financial benchmarks for (Opko Health Inc (OPK:NAS) compared to its top competitors and compared to the average for all companies within its primary industry. - Benchmarking study for (Opko Health Inc ) includes growth forecast for its primary industry to the year 2024.
The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics.
This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company’s top competitors. This report will save countless hours of research and analytical work for the end user.
Core Benefits to Customer: 1) Comprehensive benchmarks for the Subject Company: a. Benchmarked against the leading firms in its primary industry b. Benchmarked against the average for publicly-held companies (U.S.) in its industry. c. This includes financial results, ratios, vital statistics and metrics in one package, including historical and current metrics and averages for 6 years within its primary industry. 2) A snapshot overview of the company’s primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more. 3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including: a. Approximate market capitalization b. Employees c. Revenues d. Net income e. 3-Year revenue growth (%) f. 3-Year income growth (%) g. Return on assets (%) h. Return on equity (%) i. Return on invested capital (%) 4) Leading companies-profiles of the Subject Company as well as profiles of top competitors within the industry
This report is part of the Plunkett’s Corporate Benchmarks series, published by the Plunkett Analytics unit of Plunkett Research, Ltd. Plunkett Research has unique capabilities for creating corporate and industry information, due to the industry and company research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report. Similar reports are available for all significant, U.S. publicly-held firms.
Designed to benefit: - Analysis and Financial Modeling -Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants
Companies Profiled: - Johnson & Johnson - Procter & Gamble Co - Pfizer Inc - Dow Chemical Company (The) - Merck & Co Inc - Gilead Sciences Inc - AbbVie Inc - DuPont (E I du Pont de Nemours & Co) - ExxonMobil Chemical - Amgen Inc
Our reports have been used by over 10K customers, including:
The Global Data Historian Market is poised to grow at a CAGR of around XX% over the next decade to reach approximately $XX million by 2028. Some of the prominent trends that the market is witnessing include increasing demand for consolidated data for process and performance improvement, growing need for industrial 360...
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
United States Active Pharmaceutical Ingredient Market, By Method of Synthesis (Biological v/s. Synthetic), By Source (In-house v/s Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By Therapeutic Application (Cardiovascular Disease, Anti-diabetic, Oncology, Neurological Disorders, Musculoskeletal,...
The lactic acid market is estimated to be valued at USD 1.1 billion in 2020 and is projected to reach USD 2.1 billion by 2025, recording a CAGR of 12.8%, in terms of value. The polylactic acid market is estimated to be valued at USD 786 million in 2020 and is projected to reach USD 1,756 million by 2025, recording a CAGR of 17.4%, in terms...
Cannabinoids as an ingredient for use in pharmaceuticals, F&B and other industries is steadily gaining in interest across the globe, While R&D and technology developments are on the rise, the industry is still emerging considering the regulatory scenario and the technology limitations.With many technology developers focusing on overcoming...
The IR spectroscopy market is expected to grow at a CAGR of 4.1% from USD 1.0 billion in 2020 to USD 1.3 billion. Increasing demand of spectroscopy products in the healthcare & pharmaceuticals industry and food & beverages industry will drive the market. IR spectroscopy market for far-infrared technology is expected to grow...
The global mycoplasma testing market size is valued at an estimated USD 689 million in 2020 and is projected to reach USD 1,095 million by 2025, at a CAGR of 9.7% during the forecast period. The global mycoplasma testing industry’s growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical...
184 pages •
By Asia Market Information & Development Company
• Jan 2021
China’s demand for Acetic Anhydride has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
169 pages •
By Asia Market Information & Development Company
• Jan 2021
China’s demand for Dimethylformamide has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.